{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:16:44Z","timestamp":1791083804108,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["SCORE 32323B-123821"],"award-info":[{"award-number":["SCORE 32323B-123821"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"crossref","award":["32323B-139788"],"award-info":[{"award-number":["32323B-139788"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis Foundation for Medical and Biological Research"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.bbrc.2013.07.014","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T20:22:30Z","timestamp":1373919750000},"page":"32-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects"],"prefix":"10.1016","volume":"438","author":[{"given":"Marc","family":"Dufour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Dormond-Meuwly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Pythoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Demartines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Dormond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2013.07.014_b0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc839","article-title":"The phosphatidylinositol 3-Kinase AKT pathway in human cancer","volume":"2","author":"Vivanco","year":"2002","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2013.07.014_b0010","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrc2664","article-title":"Targeting PI3K signalling in cancer: opportunities, challenges and limitations","volume":"9","author":"Engelman","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bbrc.2013.07.014_b0015","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2009.25.3641","article-title":"The PI3K pathway as drug target in human cancer","volume":"28","author":"Courtney","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2013.07.014_b0020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.bbrc.2013.07.014_b0025","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Rodon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbrc.2013.07.014_b0030","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/pcmr.12007","article-title":"Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies","volume":"25","author":"Bagrodia","year":"2012","journal-title":"Pigment Cell Melanoma Res."},{"key":"10.1016\/j.bbrc.2013.07.014_b0035","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/2159-8290.CD-12-0400","article-title":"Compensatory pathways in oncogenic kinase signaling and resistance to targeted therapies: six degrees of separation","volume":"2","author":"Trusolino","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bbrc.2013.07.014_b0040","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1038\/onc.2010.626","article-title":"PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer","volume":"30","author":"Serra","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2013.07.014_b0045","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1073\/pnas.1018001108","article-title":"Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors","volume":"109","author":"Chakrabarty","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2013.07.014_b0050","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.cell.2007.06.009","article-title":"AKT\/PKB signaling: navigating downstream","volume":"129","author":"Manning","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.bbrc.2013.07.014_b0055","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0960-9822(06)00122-9","article-title":"Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha","volume":"7","author":"Alessi","year":"1997","journal-title":"Curr. Biol."},{"key":"10.1016\/j.bbrc.2013.07.014_b0060","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1126\/science.1106148","article-title":"Phosphorylation and regulation of Akt\/PKB by the rictor-mTOR complex","volume":"307","author":"Sarbassov","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2013.07.014_b0065","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.bbrc.2011.03.086","article-title":"The inhibition of MAPK potentiates the anti-angiogenic efficacy of mTOR inhibitors","volume":"407","author":"Dormond-Meuwly","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbrc.2013.07.014_b0070","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1158\/1535-7163.763.3.7","article-title":"Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling","volume":"3","author":"Ihle","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2013.07.014_b0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1158\/1078-0432.CCR-11-1558","article-title":"Antitumor activity of NVP-BKM120 \u2013 a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells","volume":"18","author":"Koul","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbrc.2013.07.014_b0080","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer","volume":"51","author":"Folkes","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bbrc.2013.07.014_b0085","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2013.07.014_b0090","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bmcl.2004.11.011","article-title":"Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors","volume":"15","author":"Lindsley","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"Pt 2","key":"10.1016\/j.bbrc.2013.07.014_b0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1042\/bj2960297","article-title":"Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses","volume":"296","author":"Arcaro","year":"1993","journal-title":"Biochem. J."},{"key":"10.1016\/j.bbrc.2013.07.014_b0100","first-page":"1093","article-title":"Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation","volume":"2","author":"Kondapaka","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbrc.2013.07.014_b0105","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.1158\/0008-5472.CAN-05-1469","article-title":"The phosphoinositide 3-kinase\/Akt pathway: a new target in human renal cell carcinoma therapy","volume":"66","author":"Sourbier","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbrc.2013.07.014_b0110","doi-asserted-by":"crossref","first-page":"e25132","DOI":"10.1371\/journal.pone.0025132","article-title":"The dual PI3K\/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer","volume":"6","author":"Roper","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2013.07.014_b0115","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ccr.2012.10.023","article-title":"JAK2\/STAT5 inhibition circumvents resistance to PI3K\/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer","volume":"22","author":"Britschgi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2013.07.014_b0120","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1002\/jcp.24065","article-title":"PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics","volume":"227","author":"Mahajan","year":"2012","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bbrc.2013.07.014_b0125","doi-asserted-by":"crossref","first-page":"e9646","DOI":"10.1371\/journal.pone.0009646","article-title":"Ack1 mediated AKT\/PKB tyrosine 176 phosphorylation regulates its activation","volume":"5","author":"Mahajan","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2013.07.014_b0130","doi-asserted-by":"crossref","first-page":"15789","DOI":"10.1074\/jbc.M212525200","article-title":"Interaction between Src and a C-terminal proline-rich motif of Akt is required for Akt activation","volume":"278","author":"Jiang","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2013.07.014_b0135","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1128\/MCB.00024-10","article-title":"Protein tyrosine kinase 6 directly phosphorylates AKT and promotes AKT activation in response to epidermal growth factor","volume":"30","author":"Zheng","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bbrc.2013.07.014_b0140","doi-asserted-by":"crossref","first-page":"37389","DOI":"10.1074\/jbc.M111.287433","article-title":"IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase\/PDK1\/mTORC2 and the pleckstrin homology domain to sustain malignant transformation","volume":"286","author":"Guo","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbrc.2013.07.014_b0145","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4049\/jimmunol.0903534","article-title":"Akt contributes to activation of the TRIF-dependent signaling pathways of TLRs by interacting with TANK-binding kinase 1","volume":"186","author":"Joung","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbrc.2013.07.014_b0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.molcel.2008.02.024","article-title":"PKBalpha\/Akt1 acts downstream of DNA-PK in the DNA double-strand break response and promotes survival","volume":"30","author":"Bozulic","year":"2008","journal-title":"Mol. Cell"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X13011546?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X13011546?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T01:45:52Z","timestamp":1688348752000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X13011546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0006291X13011546"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2013.07.014","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reactivation of AKT signaling following treatment of cancer cells with PI3K inhibitors attenuates their antitumor effects","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2013.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}